行情

GBT

GBT

全球血液疗法
NASDAQ

实时行情|Nasdaq Last Sale

27.11
+0.01
+0.04%
交易中 14:37 09/21 EDT
开盘
27.27
昨收
27.10
最高
28.23
最低
26.98
成交量
52.17万
成交额
--
52周最高
64.49
52周最低
25.48
市值
16.92亿
市盈率(TTM)
-6.3117
分时
5日
1月
3月
1年
5年
GBT 宣布参加 Cantor 全球医疗保健会议
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Cantor Global Healthcare Conference on Monday, September 27, 2021...
GlobeNewswire · 1天前
镰状细胞病药物市场:到 2030 年的行业展望、分类、需求、区域分析和预测
Research Nester released a report titled which delivers a detailed overview of the global sickle cell disease drugs market in terms of market segmentation by treatment type, disease type, end-user, and by region.
AmericaNewsHour · 5天前
GBT 成立了 GBT 基金会,以改善全球服务不足患者社区的健康和福祉
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced the launch of The GBT Foundation, a 501(c)(3) organization and source of charitable giving that will work to improve the health an...
GlobeNewswire · 09/14 15:00
Global Blood Therapeutics 总监卖出 145.00 万美元
Scott Morrison, Director at Global Blood Therapeutics (NASDAQ:GBT), made a large insider sell on September 9, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Morrison so...
Benzinga · 09/13 16:45
资本支出快速增长的三只股票
GuruFocus News · 09/09 15:53
GBT 宣布新的就业诱导补助金
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on September 1, 2021, the compensation committee of GBT's board of directors granted 20 new employees options to purchase an aggregate of 49,600 shares of the company's common stock w...
GlobeNewswire · 09/09 12:00
GBT 和美国镰状细胞病协会将举办第 10 届年度镰状细胞病 (SCD) 治疗会议
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) will host the 10 Annual Sickle Cell Disease (SCD) Therapeutics Conference on Wednesday, September 15th. The virtual conference, which takes...
GlobeNewswire · 09/08 21:05
全球血液 (GBT) 的 NDA 和 Oxbryta 的 sNDA 获得优先审查
The FDA grants priority review to Global Blood's (GBT) sNDA for Oxbryta to treat SCD in children aged four to 11 years, as well as to its NDA for a pediatric weight-based formulation of the drug.
Zacks · 09/08 13:50
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解GBT最新的财务预测,通过GBT每股收益,每股净资产,每股现金流等数据分析全球血液疗法近期的经营情况,然后做出明智的投资选择。
分析师评级

21位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测GBT价格均价为72.47,最高价位138.00,最低价为30.00。
EPS
机构持股
总机构数: 325
机构持股: 6,915.28万
持股比例: 110.80%
总股本: 6,241.21万
类型机构数股数
增持
80
687.41万
建仓
21
98.66万
减持
54
599.04万
平仓
41
301.10万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.37%
制药与医学研究
+0.72%
高管信息
President/Chief Executive Officer/Director
Ted Love
Chief Financial Officer
Jeffrey Farrow
Chief Human Resource Officer
Eric Fink
Chief Scientific Officer
Brian Cathers
Other
Jung Choi
Other
David Johnson
Other
Tricia Suvari
Lead Director/Independent Director
Mark Perry
Independent Director
Willie Brown
Independent Director
Scott Morrison
Independent Director
Deval Patrick
Independent Director
Glenn Pierce
Independent Director
Philip Pizzo
Independent Director
Dawn Svoronos
Independent Director
Alexis Thompson
Independent Director
Wendy Yarno
暂无数据
GBT 简况
Global Blood Therapeutics, Inc.是一家临床阶段的生物制药公司。该公司从事发现、开发和销售治疗血液疾病的疗法。该公司的部门从事发现、开发和销售治疗血液疾病的疗法业务。它正在开发其最初候选产品,GBT440。GBT440是一种用于治疗镰状细胞(贫血)病(SCD)每日一次剂量的口服药。该公司还正通过正在进行的I/II期临床试验中SCD受试者评估GBT440。SCD是以红细胞(RBC)破坏和闭塞血流及缺氧为标志的遗传性疾病,导致贫血、中风、多器官功能衰竭、严重疼痛危象和患者寿命缩短。GBT440抑制异常血红蛋白聚合,是RBC镰刀的具体机制。它还从事其他针对遗传性血管性水肿(HAE)的研究和开发活动。

微牛提供Global Blood Therapeutics Inc(NASDAQ-GBT)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的GBT股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易GBT股票基本功能。